Magnesium for Hypertension

Verdict: Modest, mainly for deficient or medicated patients

Magnesium supplements produce a small but real reduction in blood pressure, on the order of 1-3 mmHg overall. The benefit is concentrated in people who are magnesium-deficient or already on antihypertensive medication, and it is not a substitute for first-line treatment.

B 🟡 B Preliminary Evidence Published with Warning

🔬Why this grade7-layer evidence engine

This earns a Preliminary (B) grade because four high-quality meta-analyses agree on direction but report only a modest effect. The largest, a 2025 AHA review of 38 trials (PMID 41000008), found systolic BP fell 2.81 mmHg overall; a 2024 umbrella review of 10 meta-analyses (PMID 39280209) put it lower at 1.25 mmHg. Two earlier meta-analyses (PMID 27402922, PMID 28724644) reported similar 2-4 mmHg drops. The signal is consistent, but the size is small versus the 8-15 mmHg from standard blood-pressure drugs.

The grade stops short of A for two reasons. First, the effect is driven by specific subgroups: in medicated hypertensives systolic BP fell 7.68 mmHg and in magnesium-deficient people 5.97 mmHg (PMID 41000008), while normotensive adults saw no significant change. Second, heterogeneity between trials is high and the 2025 analysis found no clear dose-response, so the average benefit for an unselected person is genuinely modest.

Regulators and clinics mirror this caution. The US FDA allows only a qualified health claim and NIH ODS notes the evidence is inconsistent; the UK NHS, Cleveland Clinic and AHA steer people toward dietary magnesium and the DASH pattern rather than pills, and Harvard says supplements 'may modestly lower' BP. A transparency flag also applies: two of the four meta-analyses share a co-author from an advocacy-aligned magnesium research group that petitioned for the FDA claim. Bottom line: a reasonable adjunct for deficient or medicated patients, not a standalone therapy.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.60
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
B · Published with Warning
Confidence
81%
Highly consistent evidence
Evidence level
E2
Multiple high-quality MAs (≥2 independent, consistent)

How strongly each layer supports this effect

lower = less supportive
L1 ExamineGlobal benchmark
0.50
L5 Clinical bodiesAuthoritative stance
0.58
L3 MechanismPlausibility
0.65
L11 AI re-checkIndependent read
0.65
L2 PubMedPrimary literature
0.70
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.602
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (4 篇 > 0 negative)
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 1 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (4)L2 · primary research & systematic reviews

Magnesium Supplementation and Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
PMID: 41000008 2025 統合分析
Finding: Overall SBP reduced by 2.81 mmHg (95% CI -4.32 to -1.29), DBP reduced by 2.05 mmHg (95% CI -3.23 to -0.88). In hypertensives on BP medication: SBP -7.68 mmHg, DBP -2.96 mmHg. In hypomagnesemia subgroup: SBP -5.97 mmHg, DBP -4.75 mmHg. Normotensive subgroup: not significant. No dose-response relationship found.
🟢 High quality
View on PubMed
Impact of Magnesium Supplementation on Blood Pressure: An Umbrella Meta-Analysis of Randomized Controlled Trials
PMID: 39280209 2024 Umbrella Review
Finding: Overall SBP reduced by 1.25 mmHg (95% CI -1.98 to -0.51, p=0.001) and DBP reduced by 1.40 mmHg (95% CI -2.04 to -0.75, p<0.001). At >=400 mg/day, SBP fell by 6.38 mmHg and DBP by 3.71 mmHg. Effect strongest with >=12 weeks duration.
🟢 High quality
View on PubMed
The effect of magnesium supplementation on blood pressure in individuals with insulin resistance, prediabetes, or noncommunicable chronic diseases: a meta-analysis of randomized controlled trials
PMID: 28724644 2017 統合分析
Finding: SBP reduced by 4.18 mmHg (SMD -0.20; 95% CI -0.37 to -0.03) and DBP reduced by 2.27 mmHg (SMD -0.27; 95% CI -0.52 to -0.03). Larger effect than in general-population meta-analyses, supporting greater benefit in diabetic / insulin-resistant subgroup.
🟢 High quality Government
View on PubMed
Effects of Magnesium Supplementation on Blood Pressure: A Meta-Analysis of Randomized Double-Blind Placebo-Controlled Trials
PMID: 27402922 2016 統合分析
Finding: SBP reduced by 2.00 mmHg (95% CI 0.43 to 3.58) and DBP reduced by 1.78 mmHg (95% CI 0.73 to 2.82). Serum magnesium increased by 0.05 mmol/L (95% CI 0.03-0.07). Authors conclude evidence indicates a causal effect of Mg supplementation on lowering BP in adults.
🟢 High quality
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Supportive
NUTRIENT SUPPLEMENT source↗
L4b EU EFSA
Supportive
a cofactor of more than 300 enzymatic reactions source↗
L4c UK NHS
Cautious
You should be able to get all the magnesium you need by eating source↗
L4d TW TFDA / 衛福部
Supportive
每日食用量中鎂含量不超過600mg source↗
L4e WHO
Supportive
magnesium sulfate injections can be given to reduce the risk of eclampsia source↗
L5a NIH Office of Dietary Supplements
Supportive
Magnesium is a cofactor in more than 300 enzyme systems source↗
L5b Mayo Clinic
Supportive
adequate magnesium intake reduces the risk of hypertension source↗
L5c Cleveland Clinic
Neutral
magnesium and fiber all of which have been shown to improve blood pressure source↗
L5d Harvard Health
Cautious
magnesium supplements may modestly lower blood pressure source↗
L5e Specialty Society (condition-mapped)
Neutral
Calcium and magnesium are protective; they decrease blood pressure source↗
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬4 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-hypertension-INT-magnesium-001 繁體中文版 →